Nhola Lara F, Villarraga Hector R
Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, United States.
Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, United States.
Rev Esp Cardiol (Engl Ed). 2017 Jul;70(7):583-589. doi: 10.1016/j.rec.2017.02.006. Epub 2017 Mar 16.
With the rapidly rising number of patients surviving cancer, often in the setting of new or pre-existing cardiovascular disease and risk factors, a need has arisen for a specialty within the realm of cardiovascular care that can evaluate and manage these patients along with our colleagues in oncology and hematology. By the same token, all health care providers involved in the care of cancer patients with heart disease must be fully aware of the impact of adverse cardiovascular effects on the survival of these patients. Collaboration is required to mitigate the effect of cardiovascular toxicity associated with these necessary life-saving cancer therapies. The cardio-oncologist plays a pivotal role in bridging the 2 specialties, by creating a comprehensive plan to address the comorbidities as well as to provide guidance on the optimal choice of therapy. In this 3-part review, we will outline: a) the significant impact of cancer therapies on the cardiovascular health of patients with cancer and cancer survivors, b) the advantage of a multidisciplinary team in addressing these cardiovascular complications, and c) the delivery of clinical care to patients with cancer and heart disease.
随着癌症存活患者数量的迅速增加，这些患者往往伴有新的或已有的心血管疾病及风险因素，因此在心血管护理领域需要一个专业领域，能够与肿瘤学和血液学领域的同事一起对这些患者进行评估和管理。同样，所有参与癌症合并心脏病患者护理的医疗服务提供者必须充分认识到不良心血管影响对这些患者生存的影响。需要开展合作以减轻与这些必要的挽救生命的癌症治疗相关的心血管毒性作用。心脏肿瘤学家在连接这两个专业方面发挥着关键作用，通过制定全面计划来解决合并症，并为最佳治疗选择提供指导。在这篇分三部分的综述中，我们将概述：a）癌症治疗对癌症患者和癌症幸存者心血管健康的重大影响，b）多学科团队在解决这些心血管并发症方面的优势，以及c）为癌症合并心脏病患者提供临床护理。
